Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy

By Wilop Stefan   Hobe Sabine   Crysandt Martina   Esser Albert   Osieka Rainhardt   Jost Edgar  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 10, 2009-10 ,pp. : 1429-1435

Springer Publishing Company

Access to resources Recommend Favorite

Predictive value of ERCC1 and XPD polymorphism in patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a systematic review and meta-analysis

By Wei Shu-zhen  

Medical Oncology, Vol. 28, Iss. 1, 2011-03 ,pp. : 315-321

Humana Press, Inc

Access to resources Recommend Favorite

Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: A phase II trial

By Tas Faruk   Demir Cumhur   Camlica Hakan   Ustuner Zeki   Topuz Erkan  

Medical Oncology, Vol. 21, Iss. 3, 2004-09 ,pp. : 233-240

Humana Press, Inc

Access to resources Recommend Favorite

Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy

By Mori Kiyoshi   Kamiyama Yukari   Kondo Tetsuro   Kano Yasuhiko   Kodama Tetsuro  

Cancer Chemotherapy and Pharmacology, Vol. 60, Iss. 2, 2007-07 ,pp. : 189-195

Springer Publishing Company

Access to resources Recommend Favorite

Phase II trial of a 2-h infusion of gemcitabine plus carboplatin as first-line chemotherapy for advanced non-small-cell lung cancer

By Xu N.   Shen P.   Zhang X.   Yu L.   Bao H.   Shi G.   Huang S.   Chen J.   Mou H.   Fang W.  

Cancer Chemotherapy and Pharmacology, Vol. 59, Iss. 1, 2007-01 ,pp. : 1-7

Springer Publishing Company

Access to resources Recommend Favorite